Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Rigosertib + Trametinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rigosertib | ON01910 | PLK1 Inhibitor 16 | Rigosertib (ON01910) is a small molecule inhibitor of Plk1, resulting in mitotic cell-cycle arrest and inhibition of tumor growth (PMID: 15766665, PMID: 32442785). | |
Trametinib | Mekinist | GSK1120212 | MEK inhibitor (Pan) 22 MEK1 Inhibitor 20 MEK2 Inhibitor 18 | Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafinib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61H | rhabdomyosarcoma | sensitive | Rigosertib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Rigosertib (ON01910) and Mekinist (trametinib) synergistically inhibited the viability of rhabdomyosarcoma cells harboring NRAS Q61H in culture (PMID: 33158997). | 33158997 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|